Pazopanib

CAS Registry No.: 444731-52-6

Formal Name: 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide

Synonyms: GSK-VEG10003, GW786034B, Votrient

MF: C21H23N2O5S
FW: 437.5

Purity: ≥98%

Stability: ≥2 years at -20°C

Supplied as: A crystalline solid

UV/Vis: λmax 214, 271, 308 nm

**Laboratory Procedures**

For long term storage, we suggest that pazopanib be stored as supplied at -20°C. It should be stable for at least two years. Pazopanib is supplied as a crystalline solid. A stock solution may be made by dissolving the pazopanib in the solvent of choice. Pazopanib is soluble in organic solvents such as DMSO and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of pazopanib in these solvents is approximately 16.6 mg/ml.

Pazopanib is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, pazopanib should first be dissolved in DMF and then diluted with the aqueous buffer of choice. Pazopanib has a solubility of approximately 0.17 mg/ml in a 1:5 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

**Description**

Pazopanib is a broad spectrum tyrosine kinase inhibitor that blocks angiogenesis through its actions on VEGF receptors (VEGFRs). It has low nanomolar efficacy against VEGFR1 (FLT1), VEGFR2, VEGFR3 (FLT4), and KIT, as well as receptors for macrophage colony-stimulating factor 1 and platelet-derived growth factor.

Pazopanib is metabolized by the cytochrome P450 (CYP) isoform CYP3A4 and, to a lesser extent, CYP1A2 and CYP2C8. It is effective in vivo and is useful in the management of certain types of cancer.

**References**


